GH Valuation

Guardant Health Inc

Add to Watchlist

Advanced Chart

65.060

-1.45(-2.180%)1D

Overview
Forecast
Valuation
Earnings

GH Relative Valuation

GH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, GH is overvalued; if below, it's undervalued.

Historical Valuation

Guardant Health Inc (GH) is now in the Fair zone, suggesting that its current forward PS ratio of 8.28 is considered Fairly compared with the five-year average of -21.42. The fair price of Guardant Health Inc (GH) is between 15.92 to 168.82 according to relative valuation methord.

Relative Value

Fair Zone

15.92-168.82

Current Price：66.16

Fair

-35.66

Trailing

Forward

-44.52

EV/EBITDA

Guardant Health Inc. (GH) has a current EV/EBITDA of -44.52. The 5-year average EV/EBITDA is -21.62. The thresholds are as follows: Strongly Undervalued below -51.34, Undervalued between -51.34 and -36.48, Fairly Valued between -6.76 and -36.48, Overvalued between -6.76 and 8.10, and Strongly Overvalued above 8.10. The current Forward EV/EBITDA of -44.52 falls within the Undervalued range.

-22.87

EV/EBIT

Guardant Health Inc. (GH) has a current EV/EBIT of -22.87. The 5-year average EV/EBIT is -16.98. The thresholds are as follows: Strongly Undervalued below -42.63, Undervalued between -42.63 and -29.81, Fairly Valued between -4.15 and -29.81, Overvalued between -4.15 and 8.68, and Strongly Overvalued above 8.68. The current Forward EV/EBIT of -22.87 falls within the Historic Trend Line -Fairly Valued range.

8.17

Guardant Health Inc. (GH) has a current PS of 8.17. The 5-year average PS is 13.57. The thresholds are as follows: Strongly Undervalued below -10.33, Undervalued between -10.33 and 1.62, Fairly Valued between 25.53 and 1.62, Overvalued between 25.53 and 37.48, and Strongly Overvalued above 37.48. The current Forward PS of 8.17 falls within the Historic Trend Line -Fairly Valued range.

-59.33

P/OCF

Guardant Health Inc. (GH) has a current P/OCF of -59.33. The 5-year average P/OCF is -26.87. The thresholds are as follows: Strongly Undervalued below -74.24, Undervalued between -74.24 and -50.56, Fairly Valued between -3.19 and -50.56, Overvalued between -3.19 and 20.49, and Strongly Overvalued above 20.49. The current Forward P/OCF of -59.33 falls within the Undervalued range.

-37.47

P/FCF

Guardant Health Inc. (GH) has a current P/FCF of -37.47. The 5-year average P/FCF is -23.54. The thresholds are as follows: Strongly Undervalued below -67.36, Undervalued between -67.36 and -45.45, Fairly Valued between -1.63 and -45.45, Overvalued between -1.63 and 20.28, and Strongly Overvalued above 20.28. The current Forward P/FCF of -37.47 falls within the Historic Trend Line -Fairly Valued range.

Guardant Health Inc (GH) has a current Price-to-Book (P/B) ratio of -27.10. Compared to its 3-year average P/B ratio of -235.04 , the current P/B ratio is approximately -88.47% higher. Relative to its 5-year average P/B ratio of -134.84, the current P/B ratio is about -79.90% higher. Guardant Health Inc (GH) has a Forward Free Cash Flow (FCF) yield of approximately -3.23%. Compared to its 3-year average FCF yield of -9.58%, the current FCF yield is approximately -66.26% lower. Relative to its 5-year average FCF yield of -6.88% , the current FCF yield is about -53.01% lower.

-26.51

P/B

Median3y

-235.04

Median5y

-134.84

-3.28

FCF Yield

Median3y

-9.58

Median5y

-6.88

Competitors Valuation Multiple

The average P/S ratio for GH's competitors is 2.97, providing a benchmark for relative valuation. Guardant Health Inc Corp (GH) exhibits a P/S ratio of 8.17, which is 175.30% above the industry average. Given its robust revenue growth of 30.95%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Hims & Hers Health Inc

Option Care Health Inc

0.79

15.39%

4.70B

Performance Decomposition

Market capitalization of GH increased by 183.61% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -6.99 to -19.45.

The secondary factor is the Revenue Growth, contributed 30.95%to the performance.

Overall, the performance of GH in the past 1 year is driven by P/E Change. Which is more unsustainable.

30.95%

177.24M → 232.09M

Revenue Growth

-25.68%

-57.91 → -43.04

Margin Expansion

178.34%

-6.99 → -19.45

P/E Change

183.61%